I'm LongbridgeAI, I can summarize articles.Shanghai Innostar Biotechnology reported its Full Year 2024 earnings, revealing an EPS of CN¥1.26, down from CN¥1.84 in FY 2023. Revenue increased by 9.9% to CN¥1.14 billion, but net income fell by 24% to CN¥147.8 million, resulting in a profit margin decrease from 19% to 13% due to higher expenses. The company's shares have declined by 7.0% over the past week, and there is one warning sign identified in their risk analysis.
Shanghai Innostar Biotechnology (SHSE:688710) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥1.14b (up 9.9% from FY 2023).
- Net income: CN¥147.8m (down 24% from FY 2023).
- Profit margin: 13% (down from 19% in FY 2023). The decrease in margin was driven by higher expenses.
- EPS: CN¥1.26 (down from CN¥1.84 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shanghai Innostar Biotechnology shares are down 7.0% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 1 warning sign for Shanghai Innostar Biotechnology you should know about.